阿托伐他汀和瑞舒伐他汀治疗老年冠心病患者的疗效比较

doi:10.3969/j.issn.1006-6233.2019.04.025

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1320 KB) HTML (0 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the difference of efficacy between atorvastatin and rosuvastatin in the treatment of elderly patients with coronary heart disease (CHD), and to provide reference for clinical optimization of treatment. Methods: 180 elderly patients with CHD were treated in our hospital from March 2015 ~2017 to September. The age was more than 65 years old, and all were confirmed by coronary angiography (CAG). The patients were divided into the control group and the observation group by the random number table method, and the 2 groups were 90 cases each. On the basis of routine treatment, the control group took atorvastatin, 20mg/ times, 1 times /d, and the observation group took rosuvastatin, 10mg/ times and 1 times /d for 6 months. The changes of triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL-C) and low density lipoprotein cholesterol (LDL-C) were detected in 2 groups of CHD patients. The hypersensitive C reactive protein (hs-CRP) and brachial artery blood flow mediated diastolic function (FMD) were observed, and the adverse reactions of the 2 groups were statistically analyzed. Results: The 2 groups completed the treatment according to the doctor's advice, without withdrawal or falling off. After treatment, the blood lipid index TG, TC and LDL-C in the observation group were significantly lower than those in the control group and the control group (P<0.05). The serum hs-CRP in the observation group decreased significantly after treatment, and the FMD increased significantly (P<0.05) after treatment. The 2 groups were all stable and only a small amount of minor adverse symptoms appeared. The adverse reaction rate of the observation group was 8.89% (8/90), which was lower than that of the control group 11.11% (10/90), but the difference between the 2 groups was not statistically significant (P>0.05). Conclusion: Atorvastatin and rosuvastatin are both safe and effective drugs for the treatment of elderly CHD, but rosuvastatin has better effects on lipid regulation, inhibition of inflammatory reaction and improvement of vascular endothelial function.

Key words： Coronary heart disease Elderly Atorvastatin Rosuvastatin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Xiangquan
	ZHU Jianzhong
	ZHANG Mengyao

Cite this article:

LI Xiangquan,ZHU Jianzhong,ZHANG Mengyao. Comparison of Atorvastatin and Rosuvastatin in the treatment of Elderly Patients with Coronary Heart Disease[J]. HeBei Med, 2019, 25(4): 622-625.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2019.04.025 OR http://www.hbyxzzs.cn/EN/Y2019/V25/I4/622

[1] 王健.短期强化阿托伐他汀治疗对冠心病患者血清脂肪相关因子、血管内皮功能障碍及心衰发生率的影响[J].湖南师范大学学报(医学版),2017,14(6):145~148.
[2] Jiang Q,Jiayi W U,Guo Y,et al.Detection of circulating microRNA levels and vascular endothelial function indicators in patients with coronary heart disease complicated with diabetes mellitus[J].Journal of Fujian Medical University,2017,51(3):170~174.
[3] Dale C E,Fatemifar G,Palmer T M,et al.Causal associations of adiposity and body fat distribution with coronary heart disease,stroke subtypes and type 2 diabetes mellitus:a mendelian randomization analysis.[J].Circulation,2017,135(24):2373.
[4] Shek A B,Kurbanov R D,Abdullaeva G J,et al.P767Efficacy and safety of switching simvastatin intolerant patients with coronary artery disease to rosuvastatin treatment[J].European Heart Journal,2017,38(1):256~257.
[5] Beyer A M, Zinkevich N, Miller B, et al. Transition in the mechanism of flow-mediated dilation with aging and development of coronary artery disease.[J]. Basic Research in Cardiology, 2017, 112(1):5.
[6] 王鹏,严妍,于文君,等.阿托伐他汀与瑞舒伐他汀对冠心病患者的疗效与安全性对比观察[J].中国医院药学杂志,2018,38(2):169~172.
[7] Tzani A,Doulamis I,Konstantopoulos P,et al.Proteomics discovery of biomarkers in statin-treated patients with advanced coronary artery disease.[J].Atherosclerosis,2017,26(3):e241.
[8] Shen W,Li J,Niu S,et al.Effects of atorvastatin on the changes of the levels of plasma soluble ICAM-1 and soluble VCAM-1 in patients with coronary heart disease[J].Clinical Medicine,2017,13(1):142~144.
[9] Lee Y H,Viji M,Lee E,et al.Synthesis and characterization of rosuvastatin calcium impurity A;a HMG-CoA reductase inhibitor[J].Tetrahedron Letters,2017,58(26):2614~2617.
[10] 黄涛,曾恋,田井强,等.瑞舒伐他汀治疗老年冠心病合并高脂血症的机制研究[J].重庆医学,2016,45(20):2801~2803.